Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak of 2.88% and currently up by 2.52% [1][4]. Group 1: ETF Performance - The ETF's price reached a high of 0.577, with a current price of 0.569, reflecting a gain of 0.014 or 2.52% [2][6]. - The trading volume for the ETF was reported at 178,084 shares, with a turnover rate of 3.73% [6]. Group 2: Component Stocks - Notable performers among the ETF's component stocks include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1][5]. - Conversely, the stocks of Jiujiu Bio and Ascletis Pharma showed significant declines [1][5]. Group 3: Market Expectations - The JPM Healthcare Conference, held from January 12 to 15, 2026, has generated market anticipation regarding business development (BD) transaction data from Chinese innovative pharmaceutical companies, suggesting potential for increased international collaboration [6][7]. - The approval of updated labeling for the PD-1/VEGF dual antibody by the National Medical Products Administration for Kangfang Biopharma is expected to enhance treatment options for non-small cell lung cancer, indicating significant survival benefits [6][7]. Group 4: Industry Outlook - According to Western Securities, the innovative drug sector in Hong Kong is expected to maintain a structural market trend in 2026, with accelerated BD activities narrowing the price gap between Chinese and U.S. innovative drugs, leading to substantial long-term growth potential [7]. - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [7].

Core Viewpoint - China Biopharmaceutical has acquired 100% equity of Hejia Bio for 1.2 billion RMB, enhancing its position in the small RNA (siRNA) sector, following its previous acquisition of Lixin Pharmaceutical for approximately 3.5 billion RMB in July 2025 [2]. Group 1: Acquisition Details - The acquisition of Hejia Bio is a strategic move to strengthen China Biopharmaceutical's capabilities in the siRNA field, marking another significant investment after the acquisition of Shengyin Bio [2]. - Hejia Bio, established in 2018, focuses on innovative siRNA products with advantages in long-lasting effects and low dosage, boasting six delivery platforms and four innovative drugs in clinical stages [2][3]. Group 2: Product Pipeline and Innovation - Hejia Bio's Kylo-11, targeting LPA, is the world's first siRNA product to achieve "one injection per year" in clinical trials, with the first patient treated in a multi-center Phase II trial in October 2025 [3]. - In addition to Kylo-11, Hejia has three other clinical projects and over 20 preclinical pipelines covering high-value areas such as cardiovascular, metabolic, and neurological diseases [3]. Group 3: Market Expansion and Strategic Goals - The acquisition allows China Biopharmaceutical to complete its innovative drug layout in the cardiovascular field and significantly expand into major chronic disease areas such as weight management and neuropsychiatric disorders [4]. - The chairman of China Biopharmaceutical emphasized that Hejia Bio's differentiated delivery technology platform will enhance the group's core competitiveness in the siRNA sector and open up new opportunities in the global trillion-dollar chronic disease treatment market [4]. Group 4: Industry Insights - Industry experts view the acquisition as a strategic complement to China Biopharmaceutical's technical and commercialization capabilities, potentially accelerating the market introduction of Hejia's siRNA drug pipeline [5]. - The global average transaction amount for small RNA business development (BD) deals is projected to exceed 800 million USD in 2024, indicating that the acquisition aligns with the industry's growth trajectory and valuation opportunities [5].

Core Viewpoint - China Biopharmaceutical has acquired 100% equity of Hejia Bio for 1.2 billion RMB, enhancing its position in the small RNA (siRNA) sector, following its previous acquisition of Lixin Pharmaceutical for approximately 3.5 billion RMB in July 2025 [2][8]. Group 1: Acquisition Details - The acquisition of Hejia Bio is a strategic move to strengthen China Biopharmaceutical's capabilities in the small RNA field, which has seen significant stock price increases among overseas companies, with Alnylam's market value peaking at over 64 billion USD [2][5]. - Hejia Bio, established in 2018, focuses on innovative siRNA products with advantages in long-lasting effects and low dosage, boasting six delivery platforms and four innovative drugs in clinical stages [5][6]. Group 2: Product Pipeline and Market Potential - Hejia Bio's Kylo-11, targeting LPA, is the world's first siRNA product to achieve "one injection per year" in clinical trials, with the first patient treated in a multi-center phase II trial in October 2025 [6]. - The company has three additional clinical projects and over 20 preclinical pipelines covering high-value areas such as cardiovascular, metabolic, and neurological diseases [6][8]. Group 3: Strategic Implications - The acquisition allows China Biopharmaceutical to complete its innovative drug layout in the cardiovascular field and significantly expand its presence in chronic disease markets [8]. - The chairman of China Biopharmaceutical emphasized that this acquisition will enhance the company's core competitiveness in the small RNA sector and open up new opportunities in the trillion-dollar chronic disease treatment market [8].

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative pharmaceutical sector, with the CSI Hong Kong Stock Connect Innovative Drug Index rising by 2.08% as of January 13, 2026, driven by significant gains in stocks such as Rongchang Bio (+9.38%), WuXi AppTec (+7.67%), and Tigermed (+7.66) [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing AI in drug development, AI-enabled pharmaceutical supply chains, surgical robots, and intelligent diagnostic systems as key development areas, with a goal to cultivate 2-3 ecosystem-leading enterprises by 2027 [1] - The integration of AI and healthcare is seen as a clear trend, with hardware companies represented by brain-computer interfaces and surgical robots expected to benefit from policy support and technological advancements [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Innovative Drug Index include WuXi Biologics, BeiGene, Innovent Biologics, and others, accounting for a total of 71.36% of the index [2] - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest closely tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research and development, as well as services for pharmaceutical companies [2] - Investors without stock accounts can access the opportunities in the Hong Kong innovative drug industry through the Hong Kong Stock Connect Innovative Drug ETF linked fund [2]

Core Viewpoint - Nvidia and Eli Lilly are investing in AI-driven drug development, establishing a $1 billion lab in San Francisco to accelerate the process [3]. Group 1: Market Performance - Pharmaceutical stocks have seen a rise, with the Shanghai-Hong Kong-Shenzhen medical ETF and biotechnology ETFs increasing by over 4% [1]. - The Hong Kong medical ETF, which covers sectors like CXO, AI healthcare, and innovative drugs, has also shown significant gains [2]. Group 2: Investment Strategies - Huafu Securities emphasizes two short-term focuses: the upcoming JPMorgan conference for identifying outperforming stocks and the beginning of annual report disclosures [4][5]. - The annual strategy includes three main directions for innovative drugs: revenue realization, exceeding expectations in business development, and exploring cutting-edge technology platforms like gene therapy and small nucleic acids [5]. Group 3: Market Trends and Valuation - Haitong Securities notes that the Hong Kong pharmaceutical sector has shown strong performance, with a year-to-date return of 10.77%, leading among various industries [6]. - The average daily trading volume for the Hong Kong healthcare sector has increased to 14.133 billion HKD, reflecting heightened market activity [6]. - The current PE_TTM for the Hong Kong healthcare sector is recorded at 32.29, which is below the 30% percentile of the past three years, indicating relatively low valuation levels [6].

Core Viewpoint - The Chinese innovative drug sector is experiencing significant growth, highlighted by the recent clinical advancements and strategic partnerships, indicating a positive long-term trend in the industry. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (南方, 159297) rose by 2.98%, with a turnover of 53.79 million yuan and a turnover rate of 3.2% [1] - Key stocks in the index, such as Rongchang Biopharmaceuticals, Sihuan Pharmaceutical, and Boan Biotechnology, saw substantial increases of 9.38%, 7.38%, and 6.71% respectively [1] Group 2: Clinical Developments - The GLP-1 class drug, Masitide, developed in China, achieved a milestone with two pivotal Phase III clinical studies published in the prestigious journal Nature on December 18, 2025, showcasing China's drug development capabilities [1] Group 3: Strategic Partnerships - Rongchang Biopharmaceuticals announced an exclusive licensing agreement with AbbVie for RC148, receiving an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with tiered royalties on net sales outside Greater China [1] Group 4: Industry Trends - Guosen Securities noted the explosive growth in business development (BD) transactions within the Chinese innovative drug industry, emphasizing that for many domestic innovative drugs, external licensing is just the starting point for global development [2] - The Hong Kong pharmaceutical sector has shown strong performance, particularly in the biotech field, reflecting heightened market interest in innovative drugs [2] Group 5: AI Integration - Eight departments jointly issued implementation opinions on "AI + Manufacturing," focusing on AI in drug development and medical supply chains, with a goal to cultivate 2-3 leading ecological enterprises by 2027 [2] - Century Securities highlighted the significant potential of AI in enhancing pharmaceutical manufacturing, particularly in drug discovery and intelligent diagnostics, which is expected to receive ongoing policy support and capital attention [2] Group 6: Index Composition - The index tracking the Hong Kong Stock Connect Innovative Drug sector includes major companies such as CSPC Pharmaceutical Group, BeiGene, and Innovent Biologics among its top ten weighted stocks [3]

Group 1: Market Overview - The domestic market indices showed positive performance, with the Shanghai Composite Index closing at 4,165.29, up by 1.09% [4] - The SW textile and apparel sector rose by 2.65%, while the SW light industry manufacturing sector increased by 2.98%, indicating a general upward trend in the market [8] Group 2: Company Insights - Fast Retailing Group reported a revenue of 1,027.745 billion JPY for FY2026 Q1, a year-on-year increase of 14.8%, and raised its FY2026 revenue guidance to 3,800 billion JPY, up from the previous estimate of 3,570 billion JPY [6] - Ximai Foods achieved a revenue of 1.896 billion CNY in 2024, reflecting a year-on-year growth of 20.16%, and is positioned as the leading player in the oat industry in China [15][16] - Blue Sky Technology is expected to see revenues of 2.286 billion CNY in 2025, with a growth rate of 20.6%, driven by advancements in small nucleic acid technology [17] Group 3: Industry Trends - The solar energy sector experienced a decline in new installations, with a year-on-year decrease of 11.9% in November 2025, while the cumulative installed capacity for the year reached 274.89 GW, a 33.2% increase [11] - The retail sector is witnessing a shift towards community stores, as evidenced by Walmart's expansion in Shenzhen, indicating a competitive landscape in community retail [7] - The oat industry in China is projected to exceed 10 billion CNY in market size by 2024, driven by increasing health consciousness among consumers [15]

Macro and Strategy Research - The US manufacturing PMI has further declined in December 2025, marking the largest month-on-month drop since 2024, indicating a prolonged downturn for 10 months, while the service sector PMI remains strong, highlighting structural divergence in the US economy [2][3] - In China, the manufacturing PMI returned above the threshold in December 2025, with improvements in both supply and demand, while the non-manufacturing sector also showed unexpected recovery [3] Fixed Income Research - In December 2025, the central bank's liquidity net injection exceeded 800 billion, with money market rates remaining low, while the yield on 10Y government bonds rose by 1 basis point to 1.85% by the end of December [7][9] - The bond market is expected to maintain a range-bound pattern, with inflation and monetary policy acting as anchors for the upper and lower bounds of this range [9] Industry Research - The listing of Rebio Biotech on the Hong Kong Stock Exchange has increased attention on the small nucleic acid sector, with significant developments in the industry including the approval of new drugs and strategic partnerships [10][12][13] - The SW pharmaceutical index rose by 6.13% in the week of January 5-8, 2026, with all sub-sectors experiencing gains, indicating a strong market performance [13]

Investment Rating - The report maintains a positive outlook on innovative drugs and the related industry chain, indicating potential value revaluation for specific pharmaceutical companies [6][28]. Core Insights - The pharmaceutical sector in A-shares showed strong performance in the second week of January 2026, with the SW Pharma Bio index rising by 7.8%, outperforming the overall market [8][29]. - Key sub-sectors such as medical services (+12.3%), medical equipment (+9.4%), and chemical preparations (+7.3%) demonstrated significant growth during this period [13][29]. - Notable individual stock performances included Innovative Medical Management (+61.0%), Sanbo Hospital Management Group (+56.2%), and MeHow Medical (+56.1%) [15][29]. - The report highlights a normal premium level of 68.3% for the pharmaceutical sector relative to all A-shares as of January 9, 2026 [15][23]. Summary by Sections 1. Continued Focus on Innovative Drugs and Industry Chain - The report emphasizes the high prosperity in innovative drugs and suggests monitoring companies like Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical for potential value revaluation [6][28]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of January 2026, the A-share pharmaceutical sector outperformed the market, with the SW Pharma Bio index increasing by 7.8% [8][29]. - The report ranks the pharmaceutical sector as the 5th best-performing industry among Shenwan's primary industries during this period [11][29]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector outperformed the market, with the Hang Seng Healthcare index rising by 10.3% and the biotechnology sector increasing by 11.1% [20][29]. - Conversely, the U.S. pharmaceutical sector underperformed, with the S&P Healthcare Select Sector rising by only 1.1% compared to the S&P 500's 1.6% increase [20][29].

Group 1 - The core viewpoint of the article highlights the rising price of experimental monkeys, particularly for the species used in research, which has reached 140,000 yuan each, indicating a supply-demand imbalance in the market [1] - Changjiang Securities reports that the supply of experimental monkeys is decreasing while demand is stabilizing and increasing, particularly due to new technologies like small nucleic acids and CAR-T that require these monkeys, leading to a widening supply-demand gap [1] - The company, Zhaoyan New Drug, possesses valuable and scarce resources of experimental monkeys, which not only contributes to a stable profit base through annual sales but also enhances its bargaining power in a tightening supply environment, potentially leading to increased order rates and service fee premiums [1]